Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 3, 2002, Pages 346-350

  Matsuyama, Kenji ^a   Nakagawa, Kimiko ^a   Nakai, Aki ^a   Konishi, Yuriko ^a   Nishikata, Mayumi ^a   Tanaka, Hiromi ^a   Uchida, Takahiro ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Atorvastatin; Cerivastatin; Fluvastatin; Myopathy; Pravastatin; Simvastatin

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; BIOLOGICAL MARKER; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYOGLOBIN; PRAVASTATIN; SIMVASTATIN; SOLVENT; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SOLUBILITY; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY DISTAL TUBULE; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MYOPATHY; NONHUMAN; PHYSICAL CHEMISTRY; RAT; RISK ASSESSMENT; TISSUE LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; EVALUATION; KIDNEY; MALE; MUSCLE DISEASE; ORAL DRUG ADMINISTRATION; PATHOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CREATINE KINASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MUSCULAR DISEASES; RATS; RATS, WISTAR; RISK ASSESSMENT; URETHANE;

EID: 0036513380     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.346     Document Type: Article

References (22)

1. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J., N. Engl. J. Med., 333, 1301-1307 (1995).
2. The Scandinavian Simvastatin Survival Study Group, Lancet, 344, 1383-1389 (1994).
3. Nakai A., Nishikata M., Uchida T., Ichikawa M., Matsuyama K., Biol. Pharm. Bull., 20, 104-106 (1997).
4. Lopez J. R., Alamo L., Capto C., Wikinski J., Ledezma D., Muscle & Nerve, 9, 85-88 (1986).
5. Nakai A., "Drug-Drug Interaction among Hyperlipidemia Medicines," The doctoral dissertation of Mukogawa Women's University, 1997, p. 45.
6. Kalow W., Britt B. A., Terreau M. E., Haist C., Lancet, 2, 895-898 (1970).
7. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y., Biochem. Biophys. Acta, 877, 50-60 (1986).
8. Vickers S., Duncan C. A., Cher I. W., Rosegay A., Duggan D. E., Drug Metab. Dispos., 18, 138-145 (1990).
9. Vickers S., Duncan C. A., Vyas K. P., Kari P. H., Arison B., Prakash S. R., Ramjit H. G., Pitzenberger S. M., Stokker G., Duggan D. E., Drug Metab. Dispos., 18, 476-483 (1990).
10. McClellan K. J., Wiseman L. R., McTavish D., Drugs, 55, 415-420 (1998).
11. Bocan T. M. A., Ferguson E., McNally W., Uhlendorf P. D., Bak Mueller S., Dehart P., Sliskovic D. R., Roth B. D., Krause B. R., Newton R. S. Biochem. Biophys. Acta, 1123, 133-144 (1992).
12. Posvar E. L., Radulovic L. L., Cilla D. D., Jr., Whitfield L. R., Sedman A. J., J. Clin. Pharmacol., 36, 728-731 (1996).
13. Hoffman W. F., Alberts A. W., Anderson P. S., Chen J. S., Smith R. L., Willard A. K., J. Med. Chem., 29, 849-852 (1986).
14. Shimada Y., Progress in Medicine, 18, 957-962 (1998).
15. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M., Biochem. Biophys. Acta, 1045, 115-120 (1990).
16. Hatanaka T., Clin. Pharmacokinet., 39, 397-412 (2000).
17. Beaird S. L., J. Am. Pharm. Assoc., 40, 637-644 (2000).
18. Ministry of Health and Welfare of Japan, "Information on Drug Adverse Reaction," No. 119, Tokyo, 1993.
19. McTavish D., Sorkin E. M., Drugs, 42, 65-89 (1991).
20. Todd P. A., Goa K. L., Drugs, 40, 583-607 (1990).
21. Lea A. P., McTavish D., Drugs, 53, 828-847 (1997).
22. Kyrklund C , Backman J. T., Kivisto K. T., Neuvonen M., Laitila J., Neuvonen P. J., Clin. Pharmacol. Ther., 69, 340-345 (2001).